June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps
FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III Nasal Polyps Data for Dupixent").

Ono gets Asian rights to cancer cell metabolism candidate
Ono Pharmaceutical Co. Ltd. (Tokyo:4528) licensed exclusive Asian rights from Rafael Pharmaceuticals Inc. (Cranbury, N.J.) to develop and commercialize devimistat (CPI-613) for $12.9 million up front. Raphael is also eligible for $150.3 million in milestones, plus low-double digit royalties. Devimistat is in Phase III testing in the U.S. to treat pancreatic cancer and acute myelogenous leukemia. ...